Suzuken Co., Ltd. Revised Earnings Guidance for the Year Ending March 31, 2017
November 07, 2016
Share
Suzuken Co., Ltd. revised earnings guidance for the year ending March 31, 2017. For the year, the company expects net sales of ¥2,105,000 million, operating income of ¥19,900 million, ordinary income of ¥29,000 and net income attributable to owners of the parent of ¥22,300 million or ¥223.52 per share against previous guidance of net sales of ¥2,105,000 million, operating income of ¥19,900 million, ordinary income of ¥29,000 and net income attributable to owners of the parent of ¥18,500 million or ¥186.61 per share.
Suzuken Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company operates in four business segments. The Pharmaceutical Wholesale segment sells pharmaceuticals, diagnostic drugs, and medical equipment and materials, among others. The Pharmaceutical Manufacturing segment manufactures pharmaceuticals and diagnostic drugs and others. The Insurance Pharmacy segment is engaged in dispensing operations based on prescriptions from medical institutions. The Medical-related Service and Others segment is engaged in the provision of manufacturer support services, such as the transportation of medicines and comprehensive support for the distribution of drugs for rare diseases; the nursing services; the manufacture of physiological examination equipment, such as electrocardiographic monitors and blood pressure monitors; as well as other services, such as the sale of medical books.
SUZUKEN CO., LTD. 
